Alimera's New 36-Month Safety and Efficacy Results From the Phase 3 Fame(TM) Study of Iluvien(R) in Patients With Diabetic Macular Edema Presented at the 2011 Arvo Annual Meeting

Biopharmaceutical company Alimera Sciences has announced that positive new data from its completed FAME Study fo Iluvien were presented at the 2011 Association for Research in Vision of Ophthalmology (ARVO) Annual Meeting.... [more]

View complete Press Release article